Yasuhiko Hayashi

Dr. Yasuhiko Hayashi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in Pituitary
Verified
Journal Article
Closed access
PDF file
YHYasuhiko Hayashi
Yasuhiko Hayashi
DKDaisuke Kita
Daisuke Kita
MIMasayuki Iwato
Masayuki Iwato
IFIssei Fukui
Issei Fukui
MOMasahiro Oishi
Masahiro Oishi
MNMitsutoshi Nakada
Mitsutoshi Nakada

1 March 2017 in World Neurosurgery
Verified
Journal Article
Closed access
IFIssei Fukui
Issei Fukui
YHYasuhiko Hayashi
Yasuhiko Hayashi
DKDaisuke Kita
Daisuke Kita
YSYasuo Sasagawa
Yasuo Sasagawa
MOMasahiro Oishi
Masahiro Oishi
MNMitsutoshi Nakada
Mitsutoshi Nakada

1 May 2019 in Cancer Letters
Verified
Journal Article
Closed access
YKYosuke Kawahara
Yosuke Kawahara
TFTakuya Furuta
Takuya Furuta
HSHemragul Sabit
Hemragul Sabit
STSho Tamai
Sho Tamai
YDYu Dong
Yu Dong
MNMitsutoshi Nakada
Mitsutoshi Nakada

8 July 2016 in Child's Nervous System
Verified
Journal Article
Open access
YHYasuhiko Hayashi
Yasuhiko Hayashi
DKDaisuke Kita
Daisuke Kita
IFIssei Fukui
Issei Fukui
YSYasuo Sasagawa
Yasuo Sasagawa
MOMasahiro Oishi
Masahiro Oishi
MNMitsutoshi Nakada
Mitsutoshi Nakada
Symptomatic Rathke cleft cysts (RCCs) are rarely detected in neuroradiological screening and are less commonly found in children than in adults. However, when RCCs are observed in children, it is important to carefully distinguish a RCC from a cystic craniopharyngioma (CP) even if surgically treated or conservatively followed up. We conducted a retrospective review of clinical data from 11 patients with symptomatic RCCs whose ages were under 18 years and compared the data with data from 15 age- and sex-matched patients with cystic CP who were treated at our institute. The mean age of the patients with RCCs was 12.2 years (range, 6-18). There were six males and five females. As initial symptoms, nine patients presented with headache, while two each had impaired visual function, diabetes insipidus, and activity loss. The 14 patients with CP suffered from impaired visual function. Magnetic resonance imaging (MRI) mainly showed hyperintensity on T1-weighted images (WIs) and hypointensity on T2-WI in patients with RCC. However, patients with CP had characteristic hyperintensity on T2-WI. The average maximum diameter of the RCCs was 19.0 mm on average (range, 8-33 mm). The RCCs were thus significantly smaller than CPs (34.9 mm; range, 21-54 mm). The RCCs were usually oval or dumbbell-shaped and regular in appearance, while the larger CPs were lobular and irregular. A preoperative endocrinological evaluation revealed insufficiencies in four axes in five patients with RCC. Postoperative endocrinological status improved in three patients, remained unchanged in three, and worsened in one. The gonadotropin axis was damaged in a majority (nine) of the patients with CP preoperatively. Postoperative evaluation revealed deficits in five axes in 14 patients with CP, which is a significantly different trend than observed in patients with RCC. Eight patients underwent surgical procedures (transsphenoidal surgery (TSS) in four, craniotomy in four). Two of these patients experienced a recurrence of the cysts. One of these patients subsequently underwent two craniotomies followed by radiation and other underwent TSS. Among the three conservatively treated patients, two experienced a transient worsening of their symptoms along with cyst enlargement. However, none of the three conservatively treated patients required an operation. When RCCs become symptomatic in children, the most common symptom they lead to is headache. The cysts are commonly small, regular, and oval in shape. Hypointensity of cyst contents on MRI is a characteristic of RCCs, which distinguishes them from CPs. Surgical intervention can be effective and lead to the relief of symptoms without a high rate of complications. However, there seems to be a relatively high recurrence rate following surgery. Thus, if the patient's symptoms remain minor, the surgical treatment option should be used only when prudent, as the patient's symptoms may improve over time.

1 April 2018 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
MOMasahiro Oishi
Masahiro Oishi
YHYasuhiko Hayashi
Yasuhiko Hayashi
YSYasuo Sasagawa
Yasuo Sasagawa
DKDaisuke Kita
Daisuke Kita
OTOsamu Tachibana
Osamu Tachibana
MNMitsutoshi Nakada
Mitsutoshi Nakada

Verified
Journal Article
Open access
PDF file
STSho Takata
Sho Takata
HSHiromi Sakata-Haga
Hiromi Sakata-Haga
HSHiroki Shimada
Hiroki Shimada
TTTsuyoshi Tsukada
Tsuyoshi Tsukada
DSDaisuke Sakai
Daisuke Sakai
THToshihisa Hatta
Toshihisa Hatta
In rodent models, leukemia inhibitory factor (LIF) is involved in cerebral development via the placenta, and maternal immune activation is linked to psychiatric disorders in the child. However, whether LIF acts directly on neural progenitor cells (NPCs) remains unclear. This study performed DNA microarray analysis and quantitative RT-PCR on the fetal cerebrum after maternal intraperitoneal or fetal intracerebral ventricular injection of LIF at day 14.5 (E14.5) and determined that the expression of insulin-like growth factors (IGF)-1 and -2 was induced by LIF. Physiological IGF-1 and IGF-2 levels in fetal cerebrospinal fluid (CSF) increased from E15.5 to E17.5, following the physiological surge of LIF levels in CSF at E15.5. Immunostaining showed that IGF-1 was expressed in the cerebrum at E15.5 to E19.5 and IGF-2 at E15.5 to E17.5 and that IGF-1 receptor and insulin receptor were co-expressed in NPCs. Further, LIF treatment enhanced cultured NPC proliferation, which was reduced by picropodophyllin, an IGF-1 receptor inhibitor, even under LIF supplementation. Our findings suggest that IGF expression and release from the NPCs of the fetal cerebrum in fetal CSF is induced by LIF, thus supporting the involvement of the LIF–IGF axis in cerebral cortical development in an autocrine/paracrine manner.